Source comparison
Nasal Spray vs Injection
PT-141 nasal spray is available from compounding pharmacies but was rejected by the FDA for good reason. Diamond et al. (2004, PMID: 14963471) studied intranasal bremelanotide and found significant variability in blood pressure response, which led the FDA to a
This comparison does not assign a generated winner or score.
- PT-141 nasal spray is available from compounding pharmacies but was rejected by the FDA for good reason. Diamond et al. (2004, PMID: 14963471) studied intranasal bremelanotide and found significant variability in blood pressure response, which led the FDA to approve only the subcutaneous route.
- Bioavailability
- ~100%
- Variable (estimated 30-50%)
- 45-60 min
- 30-45 min
- Dose consistency
- High
- Low (congestion, technique-dependent)
- Typical dose
- 2-4 mg (higher needed due to lower bioavailability)
- FDA status
- Approved (Vyleesi)
- Not approved; compounded only
- Blood pressure effect
- Mild, predictable
- Higher variability (led to FDA rejection)
- Nausea rate
- ~40% first use
- Similar or lower
- The intranasal route requires significantly higher doses (7+ mg in the Diamond study) to achieve the same erectile response as 1.75 mg subcutaneous. This higher dosing increases systemic exposure and blood pressure variability. For users who strongly prefer avoiding injections, nasal spray is an option, but with less reliable dosing and no FDA safety data at compounded concentrations.